Cargando…

Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity

Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated i...

Descripción completa

Detalles Bibliográficos
Autores principales: Guijarro, Luis G., Cano-Martínez, David, Toledo-Lobo, M. Val, Ruiz-Llorente, Lidia, Chaparro, María, Guerra, Iván, Iborra, Marisa, Cabriada, José Luis, Bujanda, Luis, Taxonera, Carlos, García-Sánchez, Valle, Marín-Jiménez, Ignacio, Barreiro-de Acosta, Manuel, Vera, Isabel, Martín-Arranz, María Dolores, Mesonero, Francisco, Sempere, Laura, Gomollón, Fernando, Hinojosa, Joaquín, Zoullas, Sofía, Monserrat, Jorge, Menor-Salvan, Cesar, Alvarez-Mon, Melchor, Gisbert, Javier P., Ortega, Miguel A., Hernández-Breijo, Borja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945466/
https://www.ncbi.nlm.nih.gov/pubmed/35327530
http://dx.doi.org/10.3390/biomedicines10030727
_version_ 1784673965432635392
author Guijarro, Luis G.
Cano-Martínez, David
Toledo-Lobo, M. Val
Ruiz-Llorente, Lidia
Chaparro, María
Guerra, Iván
Iborra, Marisa
Cabriada, José Luis
Bujanda, Luis
Taxonera, Carlos
García-Sánchez, Valle
Marín-Jiménez, Ignacio
Barreiro-de Acosta, Manuel
Vera, Isabel
Martín-Arranz, María Dolores
Mesonero, Francisco
Sempere, Laura
Gomollón, Fernando
Hinojosa, Joaquín
Zoullas, Sofía
Monserrat, Jorge
Menor-Salvan, Cesar
Alvarez-Mon, Melchor
Gisbert, Javier P.
Ortega, Miguel A.
Hernández-Breijo, Borja
author_facet Guijarro, Luis G.
Cano-Martínez, David
Toledo-Lobo, M. Val
Ruiz-Llorente, Lidia
Chaparro, María
Guerra, Iván
Iborra, Marisa
Cabriada, José Luis
Bujanda, Luis
Taxonera, Carlos
García-Sánchez, Valle
Marín-Jiménez, Ignacio
Barreiro-de Acosta, Manuel
Vera, Isabel
Martín-Arranz, María Dolores
Mesonero, Francisco
Sempere, Laura
Gomollón, Fernando
Hinojosa, Joaquín
Zoullas, Sofía
Monserrat, Jorge
Menor-Salvan, Cesar
Alvarez-Mon, Melchor
Gisbert, Javier P.
Ortega, Miguel A.
Hernández-Breijo, Borja
author_sort Guijarro, Luis G.
collection PubMed
description Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated in the PREDICROHN project, a prospective multicenter study of the Spanish Group of Inflammatory bowel disease (GETECCU). Results: This article demonstrates declines with respect to baseline levels of serum AIF-1 in Crohn’s disease (CD) patients after 14 weeks of treatment with anti-TNFs. Furthermore, in patients with active CD (HB ≥ 5), serum AIF-1 levels were significantly higher than those in patients without activity (HB ≤ 4). The study of serum AIF-1 in the same cohort, revealed an area under the ROC curve (AUC) value of AUC = 0.66 (p = 0.014), while for the CRP (C-reactive protein), (AUC) value of 0.69 (p = 0.0066), indicating a similar ability to classify CD patients by their severity. However, the combination of data on serum levels of AIF-1 and CRP improves the predictive ability of these analyses for classifying CD patients as active (HB ≥ 5) or inactive (HB ≤ 4). When we used the odds ratio (OR) formula, we observed that patients with CRP > 5 mg/L or AIF-1 > 200 pg/mL or both conditions were 13 times more likely to show HB ≥ 5 (active CD) than were those with both markers below these thresholds. Conclusion: The development of an algorithm that includes serum levels of AIF-1 and CRP could be useful for assessing Crohn’s disease severity.
format Online
Article
Text
id pubmed-8945466
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89454662022-03-25 Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity Guijarro, Luis G. Cano-Martínez, David Toledo-Lobo, M. Val Ruiz-Llorente, Lidia Chaparro, María Guerra, Iván Iborra, Marisa Cabriada, José Luis Bujanda, Luis Taxonera, Carlos García-Sánchez, Valle Marín-Jiménez, Ignacio Barreiro-de Acosta, Manuel Vera, Isabel Martín-Arranz, María Dolores Mesonero, Francisco Sempere, Laura Gomollón, Fernando Hinojosa, Joaquín Zoullas, Sofía Monserrat, Jorge Menor-Salvan, Cesar Alvarez-Mon, Melchor Gisbert, Javier P. Ortega, Miguel A. Hernández-Breijo, Borja Biomedicines Article Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated in the PREDICROHN project, a prospective multicenter study of the Spanish Group of Inflammatory bowel disease (GETECCU). Results: This article demonstrates declines with respect to baseline levels of serum AIF-1 in Crohn’s disease (CD) patients after 14 weeks of treatment with anti-TNFs. Furthermore, in patients with active CD (HB ≥ 5), serum AIF-1 levels were significantly higher than those in patients without activity (HB ≤ 4). The study of serum AIF-1 in the same cohort, revealed an area under the ROC curve (AUC) value of AUC = 0.66 (p = 0.014), while for the CRP (C-reactive protein), (AUC) value of 0.69 (p = 0.0066), indicating a similar ability to classify CD patients by their severity. However, the combination of data on serum levels of AIF-1 and CRP improves the predictive ability of these analyses for classifying CD patients as active (HB ≥ 5) or inactive (HB ≤ 4). When we used the odds ratio (OR) formula, we observed that patients with CRP > 5 mg/L or AIF-1 > 200 pg/mL or both conditions were 13 times more likely to show HB ≥ 5 (active CD) than were those with both markers below these thresholds. Conclusion: The development of an algorithm that includes serum levels of AIF-1 and CRP could be useful for assessing Crohn’s disease severity. MDPI 2022-03-21 /pmc/articles/PMC8945466/ /pubmed/35327530 http://dx.doi.org/10.3390/biomedicines10030727 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Guijarro, Luis G.
Cano-Martínez, David
Toledo-Lobo, M. Val
Ruiz-Llorente, Lidia
Chaparro, María
Guerra, Iván
Iborra, Marisa
Cabriada, José Luis
Bujanda, Luis
Taxonera, Carlos
García-Sánchez, Valle
Marín-Jiménez, Ignacio
Barreiro-de Acosta, Manuel
Vera, Isabel
Martín-Arranz, María Dolores
Mesonero, Francisco
Sempere, Laura
Gomollón, Fernando
Hinojosa, Joaquín
Zoullas, Sofía
Monserrat, Jorge
Menor-Salvan, Cesar
Alvarez-Mon, Melchor
Gisbert, Javier P.
Ortega, Miguel A.
Hernández-Breijo, Borja
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
title Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
title_full Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
title_fullStr Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
title_full_unstemmed Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
title_short Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn’s Disease Severity
title_sort evaluation of aif-1 (allograft inflammatory factor-1) as a biomarker of crohn’s disease severity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945466/
https://www.ncbi.nlm.nih.gov/pubmed/35327530
http://dx.doi.org/10.3390/biomedicines10030727
work_keys_str_mv AT guijarroluisg evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT canomartinezdavid evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT toledolobomval evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT ruizllorentelidia evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT chaparromaria evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT guerraivan evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT iborramarisa evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT cabriadajoseluis evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT bujandaluis evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT taxoneracarlos evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT garciasanchezvalle evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT marinjimenezignacio evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT barreirodeacostamanuel evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT veraisabel evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT martinarranzmariadolores evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT mesonerofrancisco evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT semperelaura evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT gomollonfernando evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT hinojosajoaquin evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT zoullassofia evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT monserratjorge evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT menorsalvancesar evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT alvarezmonmelchor evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT gisbertjavierp evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT ortegamiguela evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity
AT hernandezbreijoborja evaluationofaif1allograftinflammatoryfactor1asabiomarkerofcrohnsdiseaseseverity